Navigation Links
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
Date:1/7/2008

SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, announced today that it has entered into a collaboration and license agreement with Pfizer Inc. to develop and commercialize its Hepatitis C virus (HCV) compound, TT-033. The collaboration will focus on completing all necessary studies for submission of an investigational new drug application (IND), as well as clinical development and commercialization of TT-033.

"We are very pleased about forming a collaborative relationship with Pfizer, and are excited about being first in the industry to partner an expressed RNAi drug," said Sara M. Hall, Chief Executive Officer of Tacere. "We have made excellent progress in the research and preclinical development of TT-033, and are very happy to be joined by Pfizer at an important time in the program's development. Pfizer recognizes the potential of this first-in- class approach to provide a novel treatment option for HCV patients and we look forward to working with the team at Pfizer to advance TT-033."

Mike Catelani, Chairman, President and CFO of Tacere, stated, "We look forward to combining Pfizer's and Tacere's complementary capabilities to take TT-033 into the clinic. We are pleased that Pfizer has chosen to work with us in developing this potential single administration RNAi drug to aid in the fight against the global healthcare crisis of HCV."

Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical research and development efforts for TT-033. Pfizer will fund all aspects of the collaboration, including the preclinical development work and will have exclusive worldwide rights, excluding all Asian countries, to commercialize products that result from the collaboration.

During the initial phase of the collaboration, Pfizer will provide Tacere with funding in order to complete the necessary IND-enabling studies
'/>"/>

SOURCE Tacere Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... not always keep hands injury-freeLAS VEGAS, Feb. 27 ... on the rise in recent years, with more than ... Many of those injuries might be prevented with better ... the 2009 Annual Meeting of the American Academy ...
... Fenofibrate treatment reduces,cardiovascular disease (CVD) ... the,composite of cardiovascular death, myocardial infarction, ... patients with type 2 diabetes and,atherogenic ... high triglyceride (2.3,mmol/L-200mg/dL or higher) and ...
Cached Medicine Technology:Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 2Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 3Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 5Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 6
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter TUESDAY, ... have abstained from sex for one year will be allowed to ... that would reverse a 31-year ban on donations from men who ... announced Tuesday its intention to release a new draft guidance in ... from gay men. The FDA is changing its policy based ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle ... News) -- Teens are more likely to start smoking ... attention-deficit hyperactivity disorder (ADHD) or conduct disorder, new ... counsel families about the risk of substance use as ... Brinkman, research director at Cincinnati Pediatric Research Group, which ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... Washington University School of Medicine in St. Louis have ... it may sound, can be an essential approach to ... culture plates containing tumor cells to see if the ... one substance had scored a hit by inhibiting growth ...
... ... Food, Water and Essentials to about 300,000 Children and Families, , ... Port-au-Prince, Haiti (Vocus) February 9, 2010 -- One ... reached nearly 300,000 children and adults in the earthquake impact zone. , , , , ...
... insert them , TUESDAY, Feb. 9 (HealthDay News) -- Larger ... profit are more likely to use feeding tubes in patients ... prolong life or help with bed sores and other problems. ... more about which hospital you go to than a decision-making ...
... , , Give a ... Diabetes Kitchen" Cookbook , CHICAGO , Feb. 9 ... for the heart with the new cookbook "The Heart-Smart Diabetes Kitchen: Fresh, ... (ADA) and CanolaInfo. Whether you cook some of these recipes for love or ...
... Boston University,s Slone Epidemiology Center have found a direct ... 2 diabetes in African American women. The study, which ... , is the first prospective study to examine the ... 2 diabetes in a large, geographically diverse cohort of ...
... , , Passage of Problem-Riddled Health Freedom ... & Thousands of Jobs , BOISE, Idaho , ... laying the groundwork to oppose a non-existent federal health care law, ... to come.  AARP is calling the Idaho Health Freedom Act (House ...
Cached Medicine News:Health News:Researchers discover new way to kill pediatric brain tumors 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 3Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Neighborhood socioeconomic status and diabetes 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4
... Electric Micro Sagittal Saw, ... 6 deg. arc. Head rotates ... any angle, and our unique ... slippage. Can also be purchased ...
... The Brasseler USA™ Battery ... quickly and efficiently determine ... STR-2000, STR-3000 Extended Run, ... Driver™, Battery Packs contain ...
... Brasseler USA™ 2002 Battery Charger is manufactured to ... 2002 Battery Charger can charge up to four ... The 2002 Charger is designed to operate on ... is a malfunction in the operation of the ...
... contain rechargeable nickel cadmium battery cells. Heat ... battery life. Strict adherence to recommended autoclave ... recommendations will shorten battery life. Warning: Battery ... of the Battery Packs to autoclave conditions ...
Medicine Products: